Published in Pharmacotherapy on November 19, 1997
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol (2000) 16.83
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst (2000) 5.62
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol (2001) 5.25
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther (2008) 4.54
Randomised, controlled trial of efficacy of midwife-managed care. Lancet (1996) 4.21
End-of-life decisions in neonatal intensive care: physicians' self-reported practices in seven European countries. EURONIC Study Group. Lancet (2000) 4.01
Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res (1999) 3.24
Parental visiting, communication, and participation in ethical decisions: a comparison of neonatal unit policies in Europe. Arch Dis Child Fetal Neonatal Ed (1999) 3.14
Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol (2000) 3.04
The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther (2012) 2.90
Randomised controlled trial of routine cervical examinations in pregnancy. European Community Collaborative Study Group on Prenatal Screening. Lancet (1994) 2.74
Medical genetic services in 31 countries: an overview. Eur J Hum Genet (1997) 2.33
Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet (1991) 2.26
Should euthanasia be legal? An international survey of neonatal intensive care units staff. Arch Dis Child Fetal Neonatal Ed (2004) 2.21
Treatment choices for extremely preterm infants: an international perspective. J Pediatr (2000) 2.19
The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther (2007) 2.18
Rural and urban differences in stage at diagnosis of colorectal and lung cancers. Br J Cancer (2001) 2.12
Drug misusers in Lothian: changes in injecting habits 1988-90. BMJ (1993) 2.09
Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest (1996) 2.02
Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta (2002) 1.98
Rural factors and survival from cancer: analysis of Scottish cancer registrations. Br J Cancer (2000) 1.97
Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther (2013) 1.94
Iatrogenic rickets in low-birth-weight infants. J Pediatr (1971) 1.90
Factors influencing time from presentation to treatment of colorectal and breast cancer in urban and rural areas. Br J Cancer (2004) 1.80
Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol (2000) 1.77
CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. Ann Oncol (2013) 1.77
The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics (1999) 1.76
Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy. Br J Cancer (2005) 1.71
Randomized European multicenter trial of surfactant replacement therapy for severe neonatal respiratory distress syndrome: single versus multiple doses of Curosurf. Pediatrics (1992) 1.71
Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer (2003) 1.70
MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics (2001) 1.70
What is the excess risk of infertility in women after genital chlamydia infection? A systematic review of the evidence. Sex Transm Infect (2007) 1.68
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer (2006) 1.66
Cyclo-oxygenase 2 inhibition in colorectal cancer therapy. Br J Surg (2003) 1.59
Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis? Ann Rheum Dis (2003) 1.59
EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group. Eur J Cancer (1996) 1.58
Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin Cancer Res (1999) 1.57
Re: population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst (2000) 1.57
Extraction of immune and inflammatory cells from human lung parenchyma: evaluation of an enzymatic digestion procedure. Clin Exp Immunol (1986) 1.57
Impact of deprivation and rural residence on treatment of colorectal and lung cancer. Br J Cancer (2002) 1.55
Disulfiram modulated ROS-MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties. Br J Cancer (2011) 1.53
Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer (2001) 1.52
Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med (1998) 1.50
Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer (2002) 1.49
Neonatal end-of-life decision making: Physicians' attitudes and relationship with self-reported practices in 10 European countries. JAMA (2000) 1.49
Thiopurine methyltransferase genotype and the toxicity of azathioprine in Japanese. Intern Med (1999) 1.48
Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol (2003) 1.48
The distribution of rods and cones in the retina of the cat (Felis domesticus). J Comp Neurol (1973) 1.47
Use of GUM services and information and views held by first time service users in a large UK city: implications for information provision. Int J STD AIDS (1997) 1.44
Effects of nerve growth factor on nerve regeneration through a vein graft across a gap. Plast Reconstr Surg (1999) 1.43
Laser capture microscopy. Mol Pathol (2000) 1.43
Mutations at codon 974 of the DPYD gene are a rare event. Br J Cancer (1997) 1.42
Stability of positive tuberculin tests: are boosted reactions valid? Am Rev Respir Dis (1991) 1.42
Newborn sickle cell disease screening: the Jamaican experience (1995-2006). J Med Screen (2007) 1.41
New transtracheal bronchoalveolar lavage technique for the diagnosis of respiratory disease in sheep. Vet Rec (2005) 1.41
Pain after vasectomy. Anaesthesia (1998) 1.39
Systematic review of cancer treatment programmes in remote and rural areas. Br J Cancer (1999) 1.39
"Healthy alliances?"--other sexual health services and their views of genitourinary medicine. Genitourin Med (1995) 1.38
A comparative study of the quality and availability of health information used to facilitate cost burden analysis of diabetes and hypertension in the Caribbean. West Indian Med J (2008) 1.38
Personal Paper: Orthopaedic scooter. Br Med J (Clin Res Ed) (1986) 1.37
The role of cholesterol and glycosylphosphatidylinositol-anchored proteins of erythrocyte rafts in regulating raft protein content and malarial infection. J Biol Chem (2001) 1.37
A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clin Pharmacol Ther (2010) 1.35
Effect of marihuana and placebo-marihuana smoking on angina pectoris. N Engl J Med (1974) 1.34
Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics (1999) 1.34
Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics (1998) 1.30
Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet (1993) 1.29
Incidence and survival for cancer in children and young adults in the North of England, 1968-1995: a report from the Northern Region Young Persons' Malignant Disease Registry. Br J Cancer (2000) 1.29
Thymidylate synthase pharmacogenetics in colorectal cancer. Clin Colorectal Cancer (2001) 1.29
Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin Pharmacol Ther (2007) 1.28
Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway. Pharmacogenomics J (2004) 1.27
Phase I and pharmacokinetic study of rhizoxin. Cancer Res (1992) 1.26
Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer (2009) 1.25
Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther (2001) 1.24
Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics (2000) 1.24
Comparative genomic hybridization and chromosomal instability in solid tumours. Br J Cancer (1999) 1.24
Phase I and pharmacokinetic study of flavone acetic acid. Cancer Res (1987) 1.24
Attitudes and practice in the management of metastatic colorectal cancer in Britain. Colorectal Cancer Working Party of the UK Medical Research Council. Clin Oncol (R Coll Radiol) (1997) 1.24
Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. J Thromb Haemost (2009) 1.22
Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clin Cancer Res (1998) 1.21
Chk1-dependent slowing of S-phase progression protects DT40 B-lymphoma cells against killing by the nucleoside analogue 5-fluorouracil. Oncogene (2006) 1.20
Thiopurine methyltransferase alleles in British and Ghanaian populations. Hum Mol Genet (1999) 1.19
Phase I and pharmacokinetic study of LM985 (flavone acetic acid ester). Cancer Res (1986) 1.19
Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population. Br J Clin Pharmacol (1996) 1.18
Strategies for enzyme/prodrug cancer therapy. Clin Cancer Res (2001) 1.18
Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res (1993) 1.18
Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin Pharmacol Ther (2007) 1.16
Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors. Ann Oncol (2002) 1.16
cis-Dichlorodiammineplatinum(II) for the treatment of advanced ovarian cancer. Cancer Treat Rep (1980) 1.15
Effect of cigarette smoking and breathing carbon monoxide on cardiovascular hemodynamics in anginal patients. Circulation (1974) 1.14
Family members as third parties in dyadic family conflict: strategies, alliances, and outcomes. Child Dev (1988) 1.13
PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer. Oncol Rep (2007) 1.11
Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer. Br J Cancer (2001) 1.09
Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int J Oncol (2001) 1.09
Controlled trial of new formulae for feeding low birth weight infants. Early Hum Dev (1986) 1.09